Title: Tildrakizumab in the treatment of PASH syndrome: A potential novel therapeutic target

Short running title: PASH syndrome and tildrakizumab

Yonatan Kok¹, Jenny Nicolopoulos¹,², George Varigos¹,², Anne Howard¹,³, Con Dolianitis¹,²

¹The Royal Melbourne Hospital, Department of Dermatology, Parkville, Victoria, Australia
²The University of Melbourne, Department of Medicine, Parkville, Victoria, Australia
³ The Western Hospital, Department of Dermatology, Footscray, Victoria, Australia

Corresponding author: Yonatan Kok
Postal address: The Royal Melbourne Hospital, Level 8 Dermatology Office, 300 Grattan Street, Parkville, Victoria, Australia, 3050
Email address: yonatan.kok@mh.org.au

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/AJD.13285

This article is protected by copyright. All rights reserved
Conflict of interest

The dermatology department at Royal Melbourne Hospital had received compassionate supplies for tildrakizumab from Sun Pharma.

Author George Varigos had received an unrestricted research grant from Sun Pharma outside the submitted work.

Case Letter

2019
Tildrakizumab in the treatment of PASH syndrome: A potential novel therapeutic strategy
Case Letter

2019

Tildrakizumab in the treatment of PASH syndrome: A potential novel therapeutic strategy

Case presentation:

PASH syndrome is a rare auto-inflammatory condition characterised by the presence of pyoderma gangrenosum (PG), acne and hidradenitis suppurativa (HS)(1). Management of this condition involves lifestyle approaches such as weight loss and smoking cessation, and, a combination of oral antibiotics, systemic therapies, biologics such as adalimumab and surgical procedures(2). Tildrakizumab is a monoclonal antibody which blocks interleukin-23, a cytokine critical in chronic auto-inflammation of the skin(3). Its use in the treatment of this condition has not been documented. We present a case of managing PASH syndrome with tildrakizumab in Australia.

This article is protected by copyright. All rights reserved
A 50-year-old man with PASH syndrome was admitted to the Royal Melbourne Hospital with a flare of his HS. He reported increasing pain over his axillae and scrotal erythematous nodules, and, developed enlarging abscesses with discharge over the scrotum. He was first diagnosed with PASH syndrome at the age of 43, with acne affecting his back and Hurley stage 3 HS of the scrotum, gluteus, thighs and axillae. His baseline abscess and nodule (AN) count was 68. His PG involved the lower legs but has remained quiescent on long-term oral prednisolone 15mg daily. Previous attempts to wean his prednisolone have resulted in a flare of his PG and HS. His prior treatment included methotrexate, infliximab, anakinra, isotretinoin and more recently, vancomycin, clindamycin and 6 weeks of ertapenem. The antibiotics partially reduced his AN count to 30.

At the time of his hospital admission, the patient had an AN count of 45. His Dermatology Life Quality Index (DLQI) score was 26, and a visual analogue scale (VAS) pain score of 10 was reported. He was treated initially with multiple scrotal wound washouts, debridement and negative pressure dressings before having a split thickness skin graft to the scrotum. Post-surgery, his antibiotics were ceased and he was commenced on two doses of tildrakizumab 100mg injections, four weeks apart, and subsequently on four-weekly 200mg injections.

Two-months after commencing tildrakizumab, the patient demonstrated a significant reduction in his AN count from 45 to 6, although, his VAS and DLQI scores were still high at 9 and 13 respectively. Further clinical improvement was observed at month 5 (see figures 1 and 2), with an AN count of 5 and VAS score of 7, but a DLQI score of 19. He was able to slowly wean his prednisolone at month 2 over 3 months with no relapse of his PG. During this time, he reported no adverse events and did not have any haematologic, hepatic or renal laboratory abnormalities. There were no other concomitant procedures or treatment prescribed and the patient did not report any other lifestyle or behavioural changes.

Although, the improvement in the patient’s HS could partially be contributed by the surgical procedures he underwent prior to starting tildrakizumab, this case represents a promising therapeutic strategy for controlling PG and treating HS in PASH syndrome. It would be important, however, to gather more clinical data in the future, evaluating its response in a larger cohort of patients, to further determine its safety and efficacy.
References:


Figures

This article is protected by copyright. All rights reserved
Figure 1. Clinical photograph of the patient's right axilla prior to starting tildrakizumab

Figure 2. Clinical photograph of the patient's right axilla 5 months after starting tildrakizumab
Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:
Kok, Y; Nicolopoulos, J; Varigos, G; Howard, A; Dolianitis, C

Title:
Tildrakizumab in the treatment of PASH syndrome: A potential novel therapeutic target

Date:
2020-04-13

Citation:

Persistent Link:
http://hdl.handle.net/11343/275621